Sangamo Therapeutics, Inc.
Deutsche BörseTotal Valuation
Sangamo Therapeutics, Inc. carries a market capitalization of 884.70M, placing it among publicly traded companies globally. Its enterprise value stands at 1.31M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 884.70M |
| Enterprise Value | 1.31M |
Share Statistics
Sangamo Therapeutics, Inc. currently has 208.20M shares outstanding.
| Shares Outstanding | 208.20M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Enterprise Valuation
| EV / Sales | 0.11 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Sangamo Therapeutics, Inc. maintains a current ratio of 1.03, meaning it holds 1.0x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 1.03 |
| Quick Ratio | 0.73 |
| Debt / Equity | 122.82 |
| Debt / EBITDA | -0.15 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -119.44 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
| Income Tax | 1.17M |
| Effective Tax Rate | N/A |
Stock Price Statistics
Sangamo Therapeutics, Inc.'s stock has declined approximately -1.38564% over the past 52 weeks. The 50-day moving average sits at 4.07, while the 200-day moving average is 5.27.
| Beta (5Y) | N/A |
| 52-Week Price Change | -1.38564% |
| 50-Day Moving Average | 4.07 |
| 200-Day Moving Average | 5.27 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -190.93M, while operating income came in at -206.46M.
| Revenue | 12.28M |
| Gross Profit | N/A |
| Operating Income | -206.46M |
| Pretax Income | -248.50M |
| Net Income | -249.67M |
| EBITDA | -190.93M |
| EBIT | -206.46M |
| Earnings Per Share (EPS) | N/A |
Balance Sheet
Sangamo Therapeutics, Inc. holds 27.79M in cash and equivalents against 29.10M in total debt, resulting in a net debt position of -27.79M. Total book value stands at -1.49B, with working capital of 1.07M providing operational flexibility.
| Cash & Cash Equivalents | 27.79M |
| Total Debt | 29.10M |
| Net Debt | -27.79M |
| Equity (Book Value) | -1.49B |
| Book Value Per Share | N/A |
| Working Capital | 1.07M |
Cash Flow
Sangamo Therapeutics, Inc. produced -173.38M in operating cash flow over the past twelve months.
| Operating Cash Flow | -173.38M |
| Capital Expenditures | -5.41M |
| Free Cash Flow | -178.79M |
| FCF Per Share | N/A |
Margins
Sangamo Therapeutics, Inc. operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -1,681.69 and net profit margin of -2,033.68 provide insight into operational efficiency.
| Gross Margin | 100.00 |
| Operating Margin | -1,681.69 |
| Pretax Margin | -2,024.15 |
| Profit Margin | -2,033.68 |
| EBITDA Margin | -1,555.21 |
Scores
Sangamo Therapeutics, Inc. posts an Altman Z-Score of -29.63, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -29.63 |